The diagnostic value of pepsinogen in atrophic gastritis and gastric cancer: meta-analysis
- VernacularTitle:Пепсиноген биомаркерын ходоодны хорт хавдар ба ходоодны хатангаршилт үрэвслийг илрүүлэх чадамж: мета-анализ
- Author:
Ganchimeg D
1
,
2
;
Bayarmaa N
1
;
Otgongerel N
2
;
Batbold B
2
;
Tegshjargal B
2
;
Sodnomtsogt L
3
;
Tulgaa L
2
Author Information
1. The Department of Gastroenterology, School of Medicine, MNUMS
2. The Department of Internal Medicine, Institute of Medical Sciences
3. Brain and mind research institute, Mongolian Academy of Sciences
- Publication Type:Journal Article
- Keywords:
Cancer screening;
Precancerous lesions;
Gastropanel;
Cancer biomarkers;
Stomach neoplasms
- From:
Mongolian Journal of Health Sciences
2025;85(1):106-114
- CountryMongolia
- Language:Mongolian
-
Abstract:
Background:The development of accurate and non-invasive diagnostic tools is essential for improving early detection of
cancers. Recent studies have shown that serum biomarkers may be useful for early detection of gastric cancer.
Aim:We aimed to evaluate the diagnostic accuracy of PGI and PGR biomarkers for detection of the gastric cancer and
atrophic gastritis.
Materials and Methods: To identify relevant studies, the MEDLINE (PubMed) database was searched using the keywords (((“Gastritis, Atrophic”[Mesh]) OR “Stomach Neoplasms”[Mesh]) AND “Pepsinogen A”[Mesh]) AND “Sensitivity and Specificity”[Mesh]). Based on the inclusion and exclusion criterias, studies were selected according to the
PRISMA guidelines. Meta-analysis was performed using Review Manager 5.4.1 and STATA/IC 15.0 (StataCorp LLC,
USA, 2017).
Results: According to the PRISMA guidelines, we selected a total of 18 studies in this meta-analysis. The meta-analysis results showed that the sensitivity of the PGI for the detection of atrophic gastritis was 58.5% (95% CI, 44.5-71.3),
specificity was 90.2% (95% CI, 68.4-97.5), and DOR was 13.0 (95% CI, 2.6-64.6); the sensitivity of the PGR was 69.9%
(95% CI, 58.1-79.5), specificity was 80.9% (95% CI, 52.4-94.2), and DOR was 9.8 (95% CI, 2.6-36.9). However, the
sensitivity of the PGI biomarkers for detecting gastric cancer was 72.6% (95% CI, 54.7-85.3), specificity was 66.9% (95%
CI, 52.5-78.7), DOR was 5.4 (95% CI, 3.1-9.3); PGR sensitivity was 77.8% (95% CI, 64.4-87.4), specificity was 65.0%
(95% CI, 53.2-75.1), DOR was 6.6 (95% CI, 3.7-11.7); PGI+PGR sensitivity was 62.3% (95% CI, 51.1-72.2), specificity
was 87.6% (95% CI, 78.0-93.3), DOR was 11.6 (95% CI, 6.8-19.8).
Conclusion: PGI and PGR tests demonstrated high specificity but moderate sensitivity. Although serum pepsinogen cannot replace endoscopy, it is considered to be an additional test and can be used to select high-risk populations.
- Full text:2025052715072052772106-114.pdf
